Aerie Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.
Aerie Pharmaceuticals has raised $88.0M across 1 funding round on record, the most recent a Post-IPO Equity of $88.0M announced in Dec 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aerie Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Dec 2021.
Aerie Pharmaceuticals Funding Rounds
Aerie Pharmaceuticals Founders and Leadership Team
Contact details for the Aerie Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Aerie Pharmaceuticals Funding Compared to Other Biotechnology Startups
Aerie Pharmaceuticals' latest round of $88.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aerie Pharmaceuticals in Biotechnology and Bedminster
Companies Similar to Aerie Pharmaceuticals
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Aerie Pharmaceuticals Funding FAQs
What does Aerie Pharmaceuticals do?
Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.
How much funding has Aerie Pharmaceuticals raised?
Aerie Pharmaceuticals has raised $88.0M across 1 round on record. The most recent is a Post-IPO Equity of $88.0M announced in Dec 2021.
When did Aerie Pharmaceuticals last raise funding?
Aerie Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $88.0M, announced in Dec 2021.
Who is the CEO of Aerie Pharmaceuticals?
Raj Kannan is listed as CEO at Aerie Pharmaceuticals.
Where is Aerie Pharmaceuticals headquartered?
Aerie Pharmaceuticals is based in Bedminster, New Jersey, United States.
How many employees does Aerie Pharmaceuticals have?
Aerie Pharmaceuticals is in the 251-500 employee band.
How does Aerie Pharmaceuticals' funding compare to other Biotechnology startups?
Aerie Pharmaceuticals' latest round of $88.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Aerie Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aerie Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.